Loestrin 24 Fe

See also: Generic Loestrin 21 1.5/30, Generic Loestrin 21 1/20, Generic Loestrin Fe 1.5/30, Generic Loestrin Fe 1/20

Loestrin 24 Fe is a brand name of ethinyl estradiol/norethindrone, approved by the FDA in the following formulation(s):

LOESTRIN 24 FE (ethinyl estradiol; norethindrone acetate - tablet; oral)

• 
  Manufacturer: WARNER CHILCOTT
  
  Approval date: February 17, 2006
  
  Strength(s): 0.02MG;1MG ^[RLD][AB]

Has a generic version of Loestrin 24 Fe been approved?

A generic version of Loestrin 24 Fe has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Loestrin 24 Fe and have been approved by the FDA:

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE (ethinyl estradiol; norethindrone acetate tablet; oral)

• 
  Manufacturer: WATSON LABS
  
  Approval date: September 1, 2009
  
  Strength(s): 0.02MG;1MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Loestrin 24 Fe. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy
  Patent 5,552,394
  Issued: September 3, 1996
  Inventor(s): Hodgen; Gary D.
  Assignee(s): The Medical College of Hampton Roads
  A method of female contraception which is characterized by a reduced incidence of breakthrough bleeding after the first cycle involves monophasicly administering a combination of estrogen and progestin for 23-25 consecutive days of a 28 day cycle in which the daily amounts of estrogen and progestin are equivalent to about 5-35 mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindrone acetate, respectively and in which the weight ratio of estrogen to progestin is at least 1:45 calculated as ethinyl estradiol to norethindrone acetate.
  
  Patent expiration dates:
  
  
  • July 22, 2014
    
    ✓ 
    Patent use: PREVENTION OF PREGNANCY
  
  

See also...

• Loestrin 24 Fe Consumer Information (Drugs.com)
• Loestrin 24 Fe Consumer Information (Cerner Multum)
• Ortho-Novum Consumer Information (Drugs.com)
• Norethindrone/Ethinyl Estradiol Consumer Information (Wolters Kluwer)
• Norethindrone/Ethinyl Estradiol (HRT) Consumer Information (Wolters Kluwer)
• Norethindrone/Ethinyl Estradiol Chewable Tablets Consumer Information (Wolters Kluwer)
• Norethindrone/Ethinyl Estradiol Tablets Consumer Information (Wolters Kluwer)
• Ethinyl estradiol and norethindrone Consumer Information (Cerner Multum)
• Ethinyl estradiol and norethindrone HRT Consumer Information (Cerner Multum)
• Norethindrone, ethinyl estradiol, and ferrous fumarate Advanced Consumer Information (Micromedex)